Investigation Report on China’s Tiotropium Bromide Markets, 2016-2020 & 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Tiotropium Bromide Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Tiotropium Bromide, developed by Boehringer Ingelheim International GmbH, is used to treat chronic obstructive pulmonary disease (COPD). Its product SPIRIVA was approved in China in 2006.

In 2017, Tiotropium Bromide inhalation powder was included in the national medical insurance catalog. By the first half of 2021, in addition to Boehringer Ingelheim International GmbH, there are Nanchang Hongyi Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Xianju Pharmaceutical Co., Ltd. in China’s Tiotropium Bromide market.

According to the market research, the sales of Tiotropium Bromide in the Chinese market have been on the rise from 2016 to 2019. Especially after the inhalation powder of Tiotropium Bromide was included in the national medical insurance catalog in 2017, its sales have grown steadily from 2017 to 2019.

However, its sales fell 19.3% year-on-year to CNY274 million in 2020. The main reason for the decline in its sales is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. The CAGR of Tiotropium Bromide in the Chinese market from 2016 to 2020 is 4.73%.

The analyst predicts that with the effective alleviation of the COVID-19 epidemic, the sales volume of Tiotropium Bromide in the Chinese market from 2021 to 2025 will have a restorative growth, promoting the increase in sales.

As of the end of 2020, the number of chronic resistance disease patients in China has increased to more than 100 million. Therefore, the sales of Tiotropium Bromide will continue to grow, promoting the growth of the Tiotropium Bromide market.

Topics Covered:

• The impact of COVID-19 on China’s Tiotropium Bromide market
• Sales value of China’s Tiotropium Bromide 2016-2020
• Competitive landscape of China’s Tiotropium Bromide market
• Prices of Tiotropium Bromide in China
• Prices of Tiotropium Bromide in China by regions and manufacturers
• Analysis of factors affecting the development of China’s Tiotropium Bromide market
• Prospect of China’s Tiotropium Bromide market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Tiotropium Bromide

1.1 Indications for Tiotropium Bromide

1.2 Development of Tiotropium Bromide in China

1.3 Governmental Approval of Tiotropium Bromide in China

1.4 The Impact of COVID-19 on Tiotropium Bromide sales in China

2 Sales of Tiotropium Bromide in China, 2016-2020

2.1 Sales Value of Tiotropium Bromide

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Tiotropium Bromide

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Tiotropium Bromide by Dosage Form in China, 2016-2020

2.3.1 Gas (Powder) Aerosol

2.3.2 Inhalation Power

3 Analysis of Major Tiotropium Bromide Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Tiotropium Bromide Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Boehringer Ingelheim International GmbH

3.2.1 Enterprise Profile

3.2.2 Sales of SPIRIVA (Boehringer Ingelheim International GmbH’s Tiotropium Bromide) in China

3.3 Nanchang Hongyi Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Hongmingrui (Nanchang Hongyi Pharmaceutical Co., Ltd.’s Tiotropium Bromide) in China

3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Tianqingsule (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Tiotropium Bromide) in China

3.5 Zhejiang Xianju Pharmaceutical Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of Biduoyi (Zhejiang Xianju Pharmaceutical Co., Ltd.’s Tiotropium Bromide) in China

4 Prices of Tiotropium Bromide for Different Manufacturers in China, 2020-2021

4.1 Boehringer Ingelheim International GmbH (SPIRIVA)

4.2 Nanchang Hongyi Pharmaceutical Co., Ltd. (Hongmingrui)

4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianqingsule)

4.4 Zhejiang Xianju Pharmaceutical Co., Ltd. (Biduoyi)

5 Prospect of Chinese Tiotropium Bromide Market, 2021-2025

5.1 Influential Factors of Chinese Tiotropium Bromide Market Development

5.1.1 The Impact of COVID-19 on Chinese Tiotropium Bromide Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

Companies Mentioned

• Boehringer Ingelheim International GmbH
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Nanchang Hongyi Pharmaceutical Co., Ltd
• Zhejiang Xianju Pharmaceutical Co., Ltd

For more information about this report visit https://www.researchandmarkets.com/r/sb77mt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900